Trial Profile

A multi-dose, crossover comparative bioavailability and pharmacokinetic study of the XRx-101 in healthy volunteers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxipurinol (Primary)
Indications Autosomal dominant polycystic kidney disease
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

07 Aug 2025 According to a XORTX Therapeutics media release, the company plans to initiate this trial in the second half of 2025 .This trial will provide critical data for population-based pharmacokinetic modeling and support future FDA and European Medicines Agency submissions.
02 Feb 2022 New trial record
31 Jan 2022 According to a XORTX Therapeutics media release, this study is expected to start in the first half of 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com